title: Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
abstract: OBJECTIVE
  To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.
  
  
  METHODS
  A total of 112 hospitalized patients with oral and maxillofacial malignancy and 28 healthy individuals were examined for serum sCD44v6 levels. Venous blood was collected from these patients and the healthy individuals. One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).
  
  
  RESULTS
  The sCD44v6 concentration was not significantly different between patients with oral and maxillofacial malignancy and control group (P > 0.05). The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05). The sCD44v6 level in patients with stage III and IV disease was higher than that of patients with stage I and II and that of the control group, but the difference was not significant (P > 0.05). Serum sCD44v6 levels in patients with OSCC after treatment became lower than that prevailed during pretreatment (P < 0.05).
  
  
  CONCLUSIONS
  The possible roles of CD44v6 in the diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation. Serum sCD44v6 may be a valuable marker in monitoring treatment response in patients with OSCC.
authors: Department of Stomatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
authors: S M
authors: SM
authors: Chang
authors: R D
authors: RD
authors: Xing
authors: F M
authors: FM
authors: Zhang
authors: Y Q
authors: YQ
authors: Duan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D003528:Carcinoma, Adenoid Cystic / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D018277:Carcinoma, Mucoepidermoid / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D016022:Case-Control Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D018960:Hyaluronan Receptors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D009367:Neoplasm Staging; D012016:Reference Values; D012468:Salivary Gland Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors